Welcome to our dedicated page for Supernus Pharma news (Ticker: SUPN), a resource for investors and traders seeking the latest updates and insights on Supernus Pharma stock.
Supernus Pharmaceuticals (SUPN) is a leading biopharmaceutical innovator focused on developing advanced treatments for central nervous system disorders. This dedicated news hub provides investors and healthcare professionals with timely updates on the company's clinical developments, regulatory milestones, and strategic initiatives in neurology and psychiatry.
Access comprehensive coverage of SUPN's progress in treating epilepsy, ADHD, and movement disorders through reformulated therapeutics. Our curated news feed includes updates on FDA submissions, partnership announcements, clinical trial results, and market expansion efforts – all essential for understanding the company's position in CNS therapeutics.
Key areas of focus include non-stimulant ADHD treatments, extended-release neurology medications, and novel approaches to Parkinson's-related conditions. Stay informed about SUPN's pipeline advancements and commercial strategies through verified press releases and objective analysis.
Bookmark this page for direct access to Supernus Pharmaceuticals' latest developments in neuroscience innovation. Check regularly for updates on product approvals, research collaborations, and financial performance indicators relevant to CNS treatment advancements.
Supernus Pharmaceuticals (Nasdaq: SUPN) plans to announce its first-quarter 2023 financial results on May 9, 2023, after market close. President and CEO Jack Khattar along with CFO Tim Dec will host a conference call at 4:30 p.m. ET to discuss these results and answer questions. The call will also be available via live webcast on the Company’s Investor Relations website. Supernus focuses on developing treatments for central nervous system (CNS) diseases, including approved products for conditions like epilepsy and Parkinson’s disease. The company also has a pipeline of novel CNS candidates aimed at various disorders.
Supernus Pharmaceuticals (Nasdaq: SUPN) has fully repaid its 0.625% Convertible Senior Notes due 2023, amounting to $402.5 million, along with $1.3 million in interest. The repayment was financed mainly using available cash and partially through a borrowing under its credit line. With this repayment, the 2023 Notes are no longer outstanding. Supernus continues to focus on developing treatments for CNS diseases, including epilepsy and Parkinson's disease, with ongoing development of novel product candidates.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced participation in two investor conferences in March 2023. The first is the Barclays Global Healthcare Conference on March 15, 2023, at the Loews Miami Beach Hotel, Florida. The second is the Jefferies Biotech on the Bay Summit on March 16, 2023, at The 1 Hotel South Beach, Florida. These events will feature management discussions focused on the company's biopharmaceutical products for central nervous system (CNS) diseases, including treatments for epilepsy and Parkinson's disease. Investors can arrange meetings with management through conference coordinators.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced that CEO Jack Khattar will participate in a fireside chat and investor meetings at the Cowen 43rd Annual Health Care Conference on March 7, 2023, at 9:50 a.m. ET. The conference runs from March 6-8, 2023, at the Boston Marriott Copley Place. Interested investors can set up meetings through the Cowen conference coordinator. A live audio webcast of Khattar's presentation will be available on Supernus' Investor Relations website, with a replay accessible for 60 days post-conference. Supernus focuses on CNS disease treatments, including epilepsy and ADHD, with ongoing development of new therapies.
FAQ
What is the current stock price of Supernus Pharma (SUPN)?
What is the market cap of Supernus Pharma (SUPN)?
